Novartis’ Myfortic Can Increase Risk Of Fetal Damage, FDA Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
The finding for the organ transplant drug follows by a month a similar warning about Roche competitor, CellCept.
You may also be interested in...
FDA Repeats Birth-Defect Risk With Roche, Novartis Transplant Drugs
PML could be a hazard, too, agency says.
FDA Repeats Birth-Defect Risk With Roche, Novartis Transplant Drugs
PML could be a hazard, too, agency says.
Novartis Adds Myfortic To Transplant Portfolio
Novartis gained approval for Myfortic (mycophenolate sodium) Feb. 27 for use in kidney transplantation